Impact of Vasopressor Selection on Kidney Outcomes in Septic Shock

Overview

This systematic review evaluates whether the choice of vasopressor influences renal outcomes in adult patients with septic shock. It highlights the limited high-quality evidence available on how different vasopressors affect acute kidney injury (AKI) incidence, renal replacement therapy (RRT) use, and longer-term kidney outcomes.

Background

Septic shock, characterized by vasopressor requirement and elevated serum lactate, carries a high mortality rate of 35–40%. Acute kidney injury (AKI) frequently complicates septic shock, significantly increasing mortality risk. Vasopressors, including catecholamines and non-adrenergic agents targeting vasopressin or the renin-angiotensin system, are central to management. Current guidelines recommend norepinephrine as first-line therapy, with vasopressin as a second agent, but evidence quality varies and renal outcomes have been understudied.

Data Highlights

The review included randomized controlled trials comparing vasopressors in adult septic shock patients, focusing on AKI incidence, duration, RRT use, and major adverse kidney events at 30 and 90 days. Definitions of AKI varied (KDIGO, AKIN, RIFLE). Searches covered multiple databases and major conference abstracts up to early 2024. No specific numerical data are provided in the excerpt.

Key Findings

• Septic shock patients are at high risk for AKI, which significantly worsens prognosis.
• Vasopressors differ in their mechanisms, potentially impacting renal perfusion and injury.
• Current guidelines recommend norepinephrine first-line, with vasopressin as an adjunct, but evidence quality is moderate to low for many comparisons.
• Most prior systematic reviews focus on mortality rather than renal outcomes, often including heterogeneous shock populations.
• There is a paucity of high-quality randomized trial data specifically addressing renal outcomes related to vasopressor choice in septic shock.
• Future research should focus on tailored vasopressor therapy considering renal risk and patient phenotypes.

Clinical Implications

Clinicians should recognize the high risk of AKI in septic shock and the potential influence of vasopressor choice on kidney outcomes. While norepinephrine remains first-line, the addition of vasopressin should be considered carefully given limited evidence on renal effects. Individualized vasopressor strategies may improve renal outcomes but require further research to guide practice.

Conclusion

The relationship between vasopressor selection and renal outcomes in septic shock remains incompletely understood due to limited high-quality evidence. This systematic review underscores the need for focused research to inform optimal vasopressor use to minimize kidney injury.

References

1. Surviving Sepsis Campaign 2021 -- Guidelines for Management of Sepsis and Septic Shock
2. KDIGO Clinical Practice Guideline for Acute Kidney Injury 2012
3. PROSPERO CRD42023481778 -- Systematic Review Protocol